에 대한 최신 뉴스 Twist Bioscience (NASDAQ:TWST) 주식

TWIST BIOSCIENCE CORP

Twist Bioscience

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.

Cathie Wood-Led Ark Invest Dumps $7M Worth Of Palantir Stock Amid Searing Rally

Equities

News

Markets

ETFs

ACCD

ACHR

ADYEY

ARKG

ARKK

ARKQ

ARKX

EXAS

IRDM

RXRX

TWST

2025년 2월 28일 금요일 캐시 우드의 아크 인베스트가 몇 가지 주목할 만한 거래를 진행했다. 그중 가장 두드러진 것은 아처 에비에이션(NYSE:ACHR), 리커션 파마슈티컬스(NASDAQ:RXRX), 템퍼스AI(NASDAQ:TEM), 그리고 이리디움 커뮤니케이션스(NASDAQ:IRDM)의 주식을 매수한 것이다.

아크 인베스트: 템퍼스AI 및 아처 에비에이션 주식 매수, 트위스트 바이오사이언스는 매각

Cathie Wood's Flurry Of Trades: Offloads $31.5M in Tesla, Buys Amazon, AMD And Meta — Dumps Palantir, Trims Robinhood And Square Amid Bitcoin Rally

Tech

ARKF

ARKW

BEAM

IBTA

ROKU

금요일에 캐시 우드가 이끄는 아크 인베스트가 이리듐 커뮤니케이션스(NASDAQ:IRDM), 트위스트 바이오사이언스(NASDAQ:TWST), 페이저듀티(NYSE:PD), 빔 테라퓨틱스(NASDAQ:BEAM), 로쿠(NASDAQ:ROKU), 그리고 아이보타(NASDAQ:IBTA)와 같은 주식들에 대해 중요한 거래를 진행했다.

아크 인베스트의 금요일 거래, 이리듐과 트위스트 바이오사이언스를 매수, 로쿠를 매도

Ark Invest's Cathie Wood Joins Call For Strategic Bitcoin Reserve, Gives Thumbs Up To Cynthia Lummis' Plan

ILMN

PATH

PLTR

캐시 우드가 이끄는 아크 인베스트가 월요일(10일)에 상당한 규모의 거래를 했다. 가장 눈에 띄는 것은 팔란티어 테크놀로지스(NASDAQ:PLTR) 주식의 매각이었는데, 팔란티어 주가가 인상적인 재무 실적 이후 계속 상승세를 이어가고 있었기 때문이다.

아크 인베스트, 팔란티어 주식 1,600만 달러 상당 추가 매각

Twist Bioscience Corporation - Common Stock

Twist Bioscience Corp

UBS initiates coverage on Bentley Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSY#NASDAQ">BSY</a>) with a Neutral rating and announces Price Target of $48.

Price Target

Initiation

Analyst Ratings

UBS Initiates Coverage On Bentley Systems with Neutral Rating, Announces Price Target of $48

Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) announced on Friday updates about its type 1 diabetes (T1D) portfolio.
The company said it would not be advancing further in VX-264 clinical trials. Vertex plans to conduct further analyses, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44545391/vertex-announces-program-updates-for-type-1-diabetes-portfolio" rel="noreferrer noopener">including of explanted devices</a>.
<ul>
<li>Vertex completed enrollment and dosing in Parts A and B of the&nbsp;Phase 1/2 VX-264 (cells + device) study and the planned analysis at Day 90 for Part B.</li>
<li>In Part B of the study, participants received the full dose of the investigational fully differentiated pancreatic islet cell therapy encapsulated in a proprietary immunoprotective device.</li>
<li>In Part B, there were two primary endpoints: safety and change in peak C-peptide during a mixed-meal tolerance test (MMTT) from baseline at Day 90.</li>
<li>VX-264 was generally safe and well tolerated; however, the study did not meet the efficacy endpoint.</li>
<li>Increases in C-peptide, a marker of insulin production, were not observed at levels necessary to deliver benefit.</li>
</ul>
Zimislecel (formerly VX-880), Vertex&#8217;s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the Phase 1/2/3 study in patients with T1D with severe hypoglycemic events (SHEs) and impaired awareness of hypoglycemia.
<ul>
<li>The is on track to complete enrollment and dosing in the first half of 2025, setting up global regulatory submissions in 2026.</li>
</ul>
Vertex is investing in expanding its manufacturing and commercial capabilities to ensure launch readiness. If approved, eligible patients across the U.S. and Europe with recurrent SHEs despite best available care could benefit from zimislecel. Vertex anticipates that initial approval could serve approximately 60,000 people with severe T1D.
Vertex is also pursuing research-stage T1D programs. These approaches include alternative immunosuppressive regimens, gene-edited hypoimmune stem-cell derived islet cell therapies, and novel devices to encapsulate islet cells.
William Blair wrote,&#8221;We view the discontinuation of VX-264 as disappointing given that this would have expanded Vertex's type 1 diabetes market significantly from that being addressed from zimislecel; however, we did not ascribe any value for the early-stage program in our model. Vertex's prioritization on the clinical advancement and potential launch of zimislecel for 60,000 severe T1D patients is prudent given the positive data to date, and approval in the T1D space would serve to further the company's diversity of commercial assets beyond cystic fibrosis and acute pain.&#8221;
Analyst Myles Minter reiterated <a href="https://www.benzinga.com/quote/VRTX/analyst-ratings" target="_blank" rel="noreferrer noopener">an Outperform rating</a>.
VRTX Price Action: Vertex stock was down 2.09% at $482.36 at publication Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44566809/eli-lillys-cholesterol-drug-reduces-genetic-heart-disease-risk-factor-by-93-9" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s Cholesterol Drug Reduces Genetic Heart Disease Risk Factor By 93.9%</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Health Care

General

VRTX

Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data

Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) announced on Monday that the ROSELLA Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer met its primary endpoint of improved progression-free survival, as assessed by blinded independent <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">central review (PFS-BICR)</a>.
In ROSELLA, patients treated with relacorilant and nab-paclitaxel chemotherapy experienced a 30% reduction in the risk of disease progression compared to patients treated with nab-paclitaxel alone.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42483672/corcept-therapeutics-fda-approved-korlym-hits-main-goal-in-cushings-syndrome-patients-with-difficult-to-control-diabetes" rel="noreferrer noopener">Corcept Therapeutics&#8217; FDA-Approved Korlym Hits Main Goal In Cushing&#8217;s Syndrome Patients With Difficult-To-Control Diabetes</a>
The median PFS-BICR was 6.5 months, compared to 5.5 months in patients who received <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44559343/primary-endpoint-met-in-corcepts-pivotal-phase-3-rosella-trial-of-relacorilant-in-patients-with-pl" rel="noreferrer noopener">nab-paclitaxel alone</a>.
At an interim evaluation of overall survival (OS), patients treated with relacorilant plus nab-paclitaxel had a significant improvement in OS, with a median OS of 16.0 months, compared to 11.5 months for patients receiving nab-paclitaxel alone.
Relacorilant was well-tolerated and no new safety signals were observed.
The complete results of ROSELLA will be presented at a medical conference this year.
The ROSELLA trial enrolled 381 patients with platinum-resistant ovarian cancer.
Analyst Reaction:
<ul>
<li>HC Wainwright maintains Corcept Therapeutics with a Buy, raising the price target <a href="https://www.benzinga.com/quote/CORT/analyst-ratings" target="_blank" rel="noreferrer noopener">from $115 to $150</a>.</li>
<li>Truist Securities maintains Corcept Therapeutics with a Buy, raising the price target from $76 to $150.</li>
</ul>
Price Action: CORT is up 85.6% at $101.80 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44544148/hb-fuller-faces-growth-hurdles-jp-morgan-analyst-slashes-price-forecast-amid-declining-sales-in-health-hygiene-and-consumable-segment" target="_blank" rel="noreferrer noopener">JP Morgan Slashes H.B. Fuller Price Forecast For Softening Growth</a></li>
</ul>
Photo: Shutterstock

Movers

Trading Ideas

CORT

Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast

11 analysts have expressed a variety of opinions on DocuSign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $97.73, a high estimate of $124.00, and a low estimate of $73.00. A decline of 1.64% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1743447689_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of DocuSign by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$124.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$81.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$73.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$98.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$124.00</td>
<td>$124.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to DocuSign. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of DocuSign compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of DocuSign's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of DocuSign's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DOCU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on DocuSign analyst ratings.</a>
<h2>All You Need to Know About DocuSign</h2>
Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.
<h3>DocuSign: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining DocuSign's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.97% as of 31 January, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: DocuSign's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 10.76%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): DocuSign's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 4.18%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): DocuSign's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 2.15%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: DocuSign's debt-to-equity ratio is below the industry average at 0.06, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DOCU

11 Analysts Have This To Say About DocuSign

Deep-pocketed investors have adopted a bullish approach towards AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ABBV usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 23 extraordinary options activities for AbbVie. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 43% leaning bullish and 21% bearish. Among these notable options, 16 are puts, totaling $1,740,435, and 7 are calls, amounting to $359,373.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $180.0 to $220.0 for AbbVie over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of AbbVie stands at 3048.78, with a total volume reaching 10,547.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in AbbVie, situated within the strike price corridor from $180.0 to $220.0, throughout the last 30 days.
<h3>AbbVie 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743447675_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$8.3</td>
<td>$8.1</td>
<td>$8.2</td>
<td>$185.00</td>
<td>$410.0K</td>
<td>114</td>
<td>500</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$3.15</td>
<td>$3.0</td>
<td>$3.05</td>
<td>$195.00</td>
<td>$305.0K</td>
<td>2.7K</td>
<td>1.2K</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$5.5</td>
<td>$5.3</td>
<td>$5.3</td>
<td>$200.00</td>
<td>$161.6K</td>
<td>4.1K</td>
<td>327</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$4.05</td>
<td>$3.9</td>
<td>$3.97</td>
<td>$205.00</td>
<td>$134.9K</td>
<td>694</td>
<td>1.2K</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$3.25</td>
<td>$3.1</td>
<td>$3.1</td>
<td>$205.00</td>
<td>$91.4K</td>
<td>694</td>
<td>558</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
In light of the recent options history for AbbVie, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of AbbVie</h3>
<ul>
<li>Currently trading with a volume of 4,607,370, the ABBV's price is up by 1.79%, now at $208.96. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 25 days.</li>
</ul>
<h3>What The Experts Say On AbbVie</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $231.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on AbbVie with a target price of $240. 
&#x2A; An analyst from B of A Securities has decided to maintain their Neutral rating on AbbVie, which currently sits at a price target of $223. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AbbVie options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

ABBV

Decoding AbbVie's Options Activity: What's the Big Picture?

Deep-pocketed investors have adopted a bearish approach towards Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TEAM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Atlassian. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 25% leaning bullish and 50% bearish. Among these notable options, 4 are puts, totaling $144,411, and 4 are calls, amounting to $145,781.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $200.0 to $260.0 for Atlassian during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Atlassian stands at 387.0, with a total volume reaching 2,441.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Atlassian, situated within the strike price corridor from $200.0 to $260.0, throughout the last 30 days.
<h3>Atlassian 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743447669_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEAM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$17.7</td>
<td>$17.6</td>
<td>$17.6</td>
<td>$210.00</td>
<td>$49.2K</td>
<td align="right">539</td>
<td>50</td>
</tr>
<tr>
<td>TEAM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$8.1</td>
<td>$7.0</td>
<td>$7.4</td>
<td>$215.00</td>
<td>$46.6K</td>
<td align="right">4</td>
<td>63</td>
</tr>
<tr>
<td>TEAM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$0.45</td>
<td>$0.2</td>
<td>$0.2</td>
<td>$260.00</td>
<td>$44.8K</td>
<td align="right">263</td>
<td>2.2K</td>
</tr>
<tr>
<td>TEAM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$59.9</td>
<td>$59.1</td>
<td>$59.66</td>
<td>$250.00</td>
<td>$35.7K</td>
<td align="right">131</td>
<td>28</td>
</tr>
<tr>
<td>TEAM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$60.5</td>
<td>$59.5</td>
<td>$59.95</td>
<td>$250.00</td>
<td>$29.9K</td>
<td align="right">131</td>
<td>41</td>
</tr>
</tbody>
</table>

<h3>About Atlassian</h3>
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
After a thorough review of the options trading surrounding Atlassian, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Atlassian Standing Right Now?</h3>
<ul>
<li>With a volume of 1,312,954, the price of TEAM is down -2.8% at $211.88. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 24 days.</li>
</ul>
<h3>What The Experts Say On Atlassian</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $295.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Stephens &amp; Co. downgraded its rating to Equal-Weight, setting a price target of $255. 
&#x2A; An analyst from Jefferies has decided to maintain their Buy rating on Atlassian, which currently sits at a price target of $330. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Atlassian with a target price of $300. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Atlassian with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

TEAM

A Closer Look at Atlassian's Options Market Dynamics

In the latest quarter, 30 analysts provided ratings for Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">11</td>
<td align="right">16</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">9</td>
<td align="right">11</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $210.37, a high estimate of $235.00, and a low estimate of $190.00. This current average has increased by 7.06% from the previous average price target of $196.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1743447666_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Snowflake. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$190.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$210.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Mark Schappel</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$215.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$221.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Thomas Blakey</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$228.00</td>
<td>$201.00</td>
</tr>
<tr>
<td>John Vinh</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$220.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$210.00</td>
<td>$187.00</td>
</tr>
<tr>
<td>Ki Bin Kim</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$203.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$215.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$205.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$220.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Bradley Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Alex Zukin</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$235.00</td>
<td>-</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Thomas Blakey</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$201.00</td>
<td>-</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$208.00</td>
<td>$185.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Snowflake. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Snowflake compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Snowflake's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SNOW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Snowflake analyst ratings.</a>
<h2>All You Need to Know About Snowflake</h2>
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that went public in 2020. To date, the company has over 3,000 customers, including nearly 30% of the Fortune 500. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to buy and ingest data, while its data solutions can be hosted on various public clouds.
<h3>Financial Insights: Snowflake</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3 months period, Snowflake showcased positive performance, achieving a revenue growth rate of 27.37% as of 31 January, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Snowflake's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -33.19%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -11.05%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Snowflake's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -3.8%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.9, Snowflake adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SNOW

Beyond The Numbers: 30 Analysts Discuss Snowflake Stock

Whales with a lot of money to spend have taken a noticeably bullish stance on Procter &amp; Gamble.
Looking at options history for Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations and 18% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $575,874 and 8, calls, for a total amount of $667,168.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $100.0 and $210.0 for Procter &amp; Gamble, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Procter &amp; Gamble's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Procter &amp; Gamble's whale trades within a strike price range from $100.0 to $210.0 in the last 30 days. 
<h3>Procter &amp; Gamble Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743447665_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$2.9</td>
<td>$2.79</td>
<td>$2.89</td>
<td>$165.00</td>
<td>$299.3K</td>
<td>2.3K</td>
<td>1.2K</td>
</tr>
<tr>
<td>PG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$1.7</td>
<td>$1.61</td>
<td>$1.63</td>
<td>$160.00</td>
<td>$168.2K</td>
<td>6.1K</td>
<td>1.1K</td>
</tr>
<tr>
<td>PG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$8.0</td>
<td>$7.75</td>
<td>$7.9</td>
<td>$165.00</td>
<td>$158.0K</td>
<td>1.4K</td>
<td>419</td>
</tr>
<tr>
<td>PG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$7.9</td>
<td>$7.75</td>
<td>$7.9</td>
<td>$165.00</td>
<td>$158.0K</td>
<td>1.4K</td>
<td>219</td>
</tr>
<tr>
<td>PG</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$6.65</td>
<td>$5.15</td>
<td>$5.95</td>
<td>$150.00</td>
<td>$108.2K</td>
<td>381</td>
<td>182</td>
</tr>
</tbody>
</table>

<h3>About Procter &amp; Gamble</h3>
Since its founding in 1837, Procter &amp; Gamble has become one of the world's largest consumer product manufacturers, with annual sales approaching $85 billion. It operates with a lineup of leading brands, including more than 20 that generate north of $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. Sales outside its home turf represent more than half of the firm's consolidated total.
In light of the recent options history for Procter &amp; Gamble, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Procter &amp; Gamble's Current Market Status</h3>
<ul>
<li>With a volume of 4,912,357, the price of PG is up 1.17% at $170.0. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 24 days.</li>
</ul>
<h3>Professional Analyst Ratings for Procter &amp; Gamble</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $165.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Procter &amp; Gamble, maintaining a target price of $165. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Procter &amp; Gamble, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Procter & Gamble Options Trading: A Deep Dive into Market Sentiment

Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $162.57, a high estimate of $182.00, and a low estimate of $148.00. This upward trend is apparent, with the current average reflecting a 20.68% increase from the previous average price target of $134.71.
<img src="https://www.benzinga.com/files/images/story/2025/1743447652_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Sea by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$165.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Navin Killa</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$176.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Jiong Shao</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$182.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Fawne Jiang</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Ranjan Sharma</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Thomas Chong</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$157.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Jiong Shao</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$148.00</td>
<td>$131.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sea. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sea compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Sea's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Sea's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sea analyst ratings.</a>
<h2>About Sea</h2>
Sea started as a gaming business, Garena, but in 2015 expanded into e-commerce. Sea operates Southeast Asia's largest e-commerce company, Shopee, in terms of gross merchandise value. Shopee is a hybrid C2C and B2C marketplace platform operating in Indonesia, Taiwan, Vietnam, Thailand, Malaysia, the Philippines, and Brazil. For Garena, Free Fire is the key revenue generating game. Sea's third business, SeaMoney, provides lending, payment, digital banking, and insurance services.As of March 31, 2024, Forrest Xiaodong Li, the founder, chairman and CEO, owned 59.8% of voting power and 18.5% of issued shares. Tencent owned 18.2% of issued shares with no voting power.
<h3>Breaking Down Sea's Financial Performance</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Sea's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 14.38%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Communication Services sector.
Net Margin: Sea's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.79% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.91%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Sea's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.07%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.49, Sea adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Sea In The Eyes Of 7 Experts

7 analysts have shared their evaluations of Varonis Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Varonis Systems, revealing an average target of $54.43, a high estimate of $67.00, and a low estimate of $45.00. This current average has decreased by 5.06% from the previous average price target of $57.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1743447638_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Varonis Systems. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$45.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$46.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Matt Dezort</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Fatima Boolani</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Jonathan Ruykhaver</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Matt Dezort</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Varonis Systems. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Varonis Systems compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Varonis Systems's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Varonis Systems's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VRNS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Varonis Systems analyst ratings.</a>
<h2>Unveiling the Story Behind Varonis Systems</h2>
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.
<h3>Varonis Systems: Delving into Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Varonis Systems displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 2.86%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -8.2%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Varonis Systems's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -2.94%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Varonis Systems's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.82%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.66.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRNS

Where Varonis Systems Stands With Analysts

In the last three months, 13 analysts have published ratings on Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Baker Hughes, revealing an average target of $53.38, a high estimate of $57.00, and a low estimate of $50.00. This current average reflects an increase of 4.67% from the previous average price target of $51.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1743447630_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Baker Hughes. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Kurt Hallead</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$55.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$54.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Derek Podhaizer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Keith Mackey</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$53.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$52.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$52.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>James West</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$52.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Marc Bianchi</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$51.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Lloyd Byrne</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$48.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Baker Hughes. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Baker Hughes compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Baker Hughes's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BKR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Baker Hughes analyst ratings.</a>
<h2>About Baker Hughes</h2>
Following a 2022 reorganization, Baker Hughes operates across two segments: oilfield services and equipment, and industrial and energy technology. The firm's oilfield services and equipment segment, or OFSE, is one of the Big Three oilfield service players, along with SLB and Halliburton, and mostly supplies to hydrocarbon developers and producers, including national oil companies, major integrated firms, and independents. Markets outside of North America buy roughly three quarters of the firm's OFSE. Baker Hughes' industrial and energy technology segment manufactures and sells turbines, compressors, pumps, valves, and related testing and monitoring services across various energy and industrial applications.
<h3>Key Indicators: Baker Hughes's Financial Health</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Baker Hughes's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 7.74%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Energy sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 16.01%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Baker Hughes's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.13% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Baker Hughes's ROA stands out, surpassing industry averages. With an impressive ROA of 3.11%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Baker Hughes's debt-to-equity ratio is below the industry average. With a ratio of 0.36, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 13 Analyst Ratings Have To Say About Baker Hughes

Ratings for Payoneer Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYO#NASDAQ">PAYO</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $11.92, with a high estimate of $16.50 and a low estimate of $8.00. This upward trend is evident, with the current average reflecting a 6.43% increase from the previous average price target of $11.20.
<img src="https://www.benzinga.com/files/images/story/2025/1743447621_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Payoneer Global's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Ashwin Shirvaikar</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.50</td>
<td>$14.50</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Nate Svensson</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$13.00</td>
<td>-</td>
</tr>
<tr>
<td>Ashwin Shirvaikar</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$13.00</td>
<td>$8.50</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Payoneer Global. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Payoneer Global compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Payoneer Global's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Payoneer Global's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PAYO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Payoneer Global analyst ratings.</a>
<h2>About Payoneer Global</h2>
Payoneer Global Inc is a financial technology company purpose-built to enable the world's small and medium-sized businesses (SMB(s)) to grow and operate their businesses around the world by reliably and securely connecting them to the digital economy. The company started to empower commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
<h3>Breaking Down Payoneer Global's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Payoneer Global's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 16.68%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 6.95%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Payoneer Global's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.5%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.24%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Payoneer Global's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.03.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PAYO

Breaking Down Payoneer Global: 6 Analysts Share Their Views

In the current market session, Herc Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRI#NYSE">HRI</a>) share price is at $138.85, after a 0.06% drop. Over the past month, the stock went up by 4.65%, but over the past year, it actually decreased by 17.00%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1743447620_0.png" alt="Past Year Chart" />

<h3>Herc Holdings P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Herc Holdings has a lower P/E than the aggregate P/E of 21.28 of the Trading Companies &amp; Distributors industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1743447620_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for Herc Holdings

WIIM

Gold is trading higher as uncertainty surrounding tariffs increases demand for the safe-haven asset.

H.C. Wainwright initiated coverage on Virax Biolabs Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>), a U.K.-based company focused on detecting immune responses and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">diagnosing viral diseases</a>.
Virax Biolabs is developing T cell-based test technologies to provide an immunology profiling platform. T-cell testing can be particularly effective in diagnosing and therapeutics for post-viral syndromes (such as Long COVID and other chronic conditions linked to immune dysregulation).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43936048/exclusive-virax-biolabs-says-its-tech-fits-rfk-jr-s-hhs-goals-on-vaccine-transparency" rel="noreferrer noopener">EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.&#8217;s HHS Goals On Vaccine Transparency</a>
The ViraxImmune platform is developing an adaptable test to detect the body's immune response to various conditions associated with chronic inflammation and T-cell exhaustion. Utilizing peptide pools to activate memory T cells and measure&nbsp;specific cytokine profiles related to various infections, ViraxImmune is designed to address multiple diseases and research needs.
The ViraxImmune <a target="_blank" href="https://viraxbiolabs.com/viraximmune/" rel="noreferrer noopener">platform</a> will be available initially for research use only (RUO) before in vitro diagnostics (IVD) approval. It can analyze the activation of cells involved in the immune response, providing unparalleled insights into complex diseases and infections.
Analyst Yi Chen writes that Virax is slated to meet with the FDA in mid-2025 to define the approval pathway and potentially begin a U.S.-based clinical validation study in the second half of 2025.
The analyst has initiated with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/VRAX/analyst-ratings" rel="noreferrer noopener">price target of $3</a>.
HC Wainwright writes that Virax estimates that between 254,000 and 301,000 patients annually could benefit from Virax T cell exhaustion-based IVD.
The analyst estimates that long COVID cases alone could create a diagnostics market worth hundreds of millions of dollars. Meanwhile, there are currently no reliable tests for conditions linked to post-acute infection syndrome&nbsp;(PAIS).
&#8220;Therefore, we believe there is an attractive market opportunity for ViraxImmune-based diagnostic tests,&#8221; analyst Chen writes.
Earlier in March, Virax Biolabs started enrolling patients into its&nbsp;United Kingdom-based, multi-center clinical study to assess the ViraxImmune FluoroSpot T cell assay performance in detecting T cell dysfunction in post-acute infection syndrome patients.
Up to 200 participants will be enrolled in the study, and initial data from this longitudinal assessment are <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44373591/virax-biolabs-enrolls-first-patients-in-clinical-study-assessing-t-cell-dysfunction-in-post-acute-" rel="noreferrer noopener">expected in Q2 2026</a>.
Price Action: VRAX stock is trading flat at $1.16 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/03/44566020/arm-aims-for-50-data-center-cpu-market-share-by-2025-challenging-intel-and-amd" target="_blank" rel="noreferrer noopener">Arm Aims for 50% Data Center CPU Market Share by 2025, Challenging Intel and AMD</a></li>
</ul>
Photo via Shutterstock.

VRAX

Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating

With increased market volatility comes a revived interest in portfolio diversification. Allspring Global Investments took a chance to introduce two newly launched actively managed ETFs: the Allspring LT Large Cap Growth ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGRW#NYSE">AGRW</a>) and the Allspring Special Large Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASLV#NYSE">ASLV</a>).
The funds are designed to grant investors <a href="https://www.benzinga.com/etfs">direct access to mispriced stocks</a> and value ideas in the large-cap universe to meet the immediate needs of the current market.
Allspring Global Head of Product Development and Innovation Rick Genoni <a href="https://www.prnewswire.com/news-releases/allspring-launches-actively-managed-equity-etfs-302412171.html">said</a>, &#8220;After a long period when the stock market was dominated by a handful of large tech companies, we see financial advisors and their clients growing increasingly interested in efficiently diversifying their equity market exposure through active portfolio management. We think these strategies in this format were made for this moment.&#8221;  
Also Read: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/03/44547975/sticky-inflation-weighs-on-markets-spy-qqq-tech-stocks-take-a-hit">Sticky Inflation Weighs On Markets — SPY, QQQ, Tech Stocks Take A Hit</a>
Both ETFs have an expense ratio of 0.35%, providing cost-effective access to actively managed large-cap strategies.
AGRW seeks to find mispriced large-cap U.S. equities within the S&amp;P 500 Index through a bottom-up, research-based approach. The fund seeks to obtain a concentrated portfolio of approximately 50 securities via an in-house valuation model.
Conversely, ASLV uses a value investing approach. It seeks high-quality companies trading at less than their intrinsic value in the Russell 1000 Index, with the ability to invest up to 20% in foreign stocks, including American depositary receipts. The fund holds between 30 to 50 stocks, with an emphasis on companies that have good management and flexible balance sheets.
Though both the funds invest in large-cap stocks, AGRW&#8217;s investment universe is comprised of S&amp;P 500 Index constituents, while ASLV holds against the Russell 1000 Index.
Allspring&#8217;s recent action underscores its push to grow its ETF offerings. After introducing three fixed-income ETFs in December 2024 — the Allspring Broad Market Core Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFIX#NYSE">AFIX</a>), the Allspring Income Plus ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AINP#NYSE">AINP</a>) and the Allspring Core Plus ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APLU#NYSE">APLU</a>) — the firm now oversees nearly $590 million in ETF assets, wrote etftrends.com. The new equity funds further increase Allspring&#8217;s product slate, giving investors more tools to ride out the changing market landscape.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/03/44544012/auto-etfs-tumble-after-trumps-25-import-tariff-move-on-vehicles-made-overseas">Auto ETFs Tumble After Trump&#8217;s 25% Import Tariff Move On Vehicles Made Overseas</a></li>
</ul>
Photo: Shutterstock

New ETFs

AFIX

AGRW

AINP

APLU

ASLV

Growth Or Value? Allspring's New ETFs Offer Both

Investors continue to brace for volatility ahead of U.S. President Donald Trump&#8217;s tariff announcement this week. Fundstrat's Tom Lee&nbsp;believes bullish traders <a href="https://www.benzinga.com/trading-ideas/25/03/44566164/exclusive-could-trumps-liberation-day-reciprocal-tariffs-crash-the-stock-market-48-say-this">will get rewarded.</a> 
What To Know: Lee indicated that the stock market is showing signs of bottoming this week.
Lee noted Monday on CNBC&#8217;s &#8220;Squawk Box&#8221; that markets are oversold right now, and investors have already de-risked heavily ahead of Trump&#8217;s reciprocal tariff announcement on Wednesday.
&#8220;Post-Wednesday, I think markets are going to have some visibility. That allows us to take some of the selling pressure off,&#8221; Lee said on the show.
He told CNBC that with so many people thinking the economy could &#8220;completely fall off the rails&#8221; after Wednesday, markets could actually have the &#8220;right pieces&#8221; in place for a bottom following the tariff announcements.
Check This Out: <a href="https://www.benzinga.com/markets/equities/25/03/44562306/are-we-heading-into-a-bear-market">Are We Heading Into A Bear Market?</a>
The Trump administration&#8217;s tariffs have led to heightened concerns about <a href="https://www.benzinga.com/markets/equities/25/03/44554304/goldman-sachs-raises-us-recession-risk-to-35-expects-inflation-at-3-5-in-2025-amid-tariff-uncertainties-economist-mohamed-el-erian-highlights-stagflationary-twist">stagflation</a>, which is a period of slow economic growth paired with high inflation. Lee noted that there are a lot of &#8220;distortions&#8221; in the data as tariffs have caused a pull forward in demand in some categories.
&#8220;I think it&#8217;s possible economists are only dialing in the negative consequences so far, but not the positive &#8230; We might end up having better growth, so less stag, and maybe the inflation stuff is more distorting so it&#8217;s not as stagflationary,&#8221; Lee said.
&#8220;Not that I&#8217;m saying it&#8217;s going to [cause] a reversal of markets here, but I think investors are a little too scared heading into Wednesday.&#8221;
Lee told CNBC that he also believes the Federal Reserve appears more dovish than most expected. The Fed was not as hawkish as most were anticipating after the FOMC meeting earlier this month and Lee expects that to continue this week.
Fed Chair Jerome Powell is set to speak at the Society for Advancing Business Editing and Writing&#8217;s annual conference following Friday's nonfarm payrolls report. The Fed chair&#8217;s speech is expected to be focused on the economic outlook.
The S&amp;P 500 officially fell into correction territory earlier this month. The SPDR S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was last down 0.46% at $553.16 on Monday, but well off the lows of the session, according to data from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44566197/coreweave-ipo-performance-likely-due-to-company-not-ai-sector-analyst-says-investor-sentiment-remains-mixed">CoreWeave IPO Performance Likely Due To Company, Not AI Sector: Analyst Says &#8216;Investor Sentiment Remains Mixed&#8217;</a></li>
</ul>
Photo: Shutterstock.

Long Ideas

Tom Lee Sees 'Right Pieces' For A Market Bottom: 'Investors Are A Little Too Scared Heading Into Wednesday'

<a href="https://x.com/rogoswami/status/1906777484927898040?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet" title="https://x.com/rogoswami/status/1906777484927898040?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet">https://x.com/rogoswami/status/1906777484927898040?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet</a>

'Nippon Steel's Takahiro Mori is slated to meet with Commerce Secy Howard Lutnick tomorrow, according to people familiar. The two are expected to discuss Nippon's outstanding offer to increase its blast furnace investment.' -Semafor Reporter

The Trump family has significantly increased its control over World Liberty Financial, <a href="https://www.benzinga.com/25/03/44475966/trump-backed-world-liberty-financial-confirms-dollar-stablecoin-plans-with-bitgo">a decentralized finance platform still under development</a>. 
What Happened: According to a Reuters report published Monday, the shift follows a second WLFI token sale in January that brought the platform's total <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44327489/trump-backed-world-liberty-financial-raises-590m-in-token-sales?adt_ei=%7B%7Bemail%7D%7D&amp;he=%7B%7Bemail%7D%7D&amp;el=FutureFinance">fundraising to $550 million</a>.
Two of the platform's original co-founders, Zak Folkman and Chase Herro, have reportedly been removed from their positions as controlling parties. 
A newly established parent company, WLF Holdco LLC—60% owned by DT Marks DeFi LLC, an entity linked to Donald Trump and his family—now oversees the protocol's development and governance. 
The Trump-affiliated entity replaces Folkman and Herro as the sole directors of World Liberty Financial Inc., according to corporate disclosures.
World Liberty had previously stated that the Trump family would be entitled to 75% of the net revenue from WLFI token sales. 
That share, combined with the new corporate structure, gives the Trump family substantial control over both the platform and its financial outcomes. 
In total, they hold at least 22.5 billion WLFI tokens out of a 100 billion cap and are also entitled to 60% of protocol-generated revenues once the lending and finance features go live.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44567164/circle-eyes-5-billion-valuation-for-upcoming-initial-public-offering">Circle Eyes $5 Billion Valuation For Upcoming Initial Public Offering</a>
Why It Matters: This is <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44560290/trump-family-to-dive-into-bitcoin-mining-after-defi-meme-coin-projects">not the Trump family's first crypto foray</a>.
Donald Trump was introduced as World Liberty's "chief crypto advocate" during the platform's October launch. 
His sons Eric and Donald Jr. were named "web3 ambassadors," while Barron Trump was given the title of "chief DeFi visionary." 
The project also lists Zach Witkoff, son of real estate developer Steven Witkoff, and Paxos co-founder Rich Teo as early contributors. 
Eric Trump also serves on the board of WLF Holdco LLC.
The WLFI token sales have attracted over 85,000 participants, with nearly 70% of funds coming from wallets spending $100,000 or more. 
Notably, Tron founder Justin Sun reportedly purchased $75 million worth of WLFI. 
Other crypto entities, including Movement Labs and tokenization firm Ondo Finance (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ONDO</a>), have announced collaborations with the platform, and on-chain data shows World Liberty's treasury holds their native tokens.
While World Liberty's treasury once held over $360 million in assets—including (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WBTC</a>), and (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>)—it liquidated over 90% of those holdings before starting to buy back tokens. 
The current treasury balance is estimated to be over $80 million.
Plans for the platform's "lend and borrow" market are reportedly nearing launch, alongside a personal finance app. 
Additionally, the team is developing USD1, a U.S. dollar-backed stablecoin that will be issued on Ethereum and Binance Smart Chain.
However, some in the crypto space, including Ethereum co-founder Vitalik Buterin, have raised concerns about political figures using token launches as potential tools for influence or corruption.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44566443/blackrock-ceo-larry-fink-says-bitcoin-can-rival-dollar-as-global-reserve-currency">BlackRock CEO Larry Fink Says Bitcoin Can Rival Dollar As Global Reserve Currency</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

$ONDO

$USDT

$WBTC

Trump Family Tightens Grip On DeFi Platform World Liberty Financial

Deep-pocketed investors have adopted a bullish approach towards Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in OKTA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Okta. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 62% leaning bullish and 25% bearish. Among these notable options, 5 are puts, totaling $291,975, and 3 are calls, amounting to $113,626.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75.0 to $115.0 for Okta over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Okta options trades today is 548.5 with a total volume of 671.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Okta's big money trades within a strike price range of $75.0 to $115.0 over the last 30 days.
<h3>Okta 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743446757_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>OKTA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$14.2</td>
<td>$14.15</td>
<td>$14.15</td>
<td>$105.00</td>
<td>$118.8K</td>
<td>22</td>
<td align="right">113</td>
</tr>
<tr>
<td>OKTA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$6.35</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$105.00</td>
<td>$62.0K</td>
<td>1.2K</td>
<td align="right">115</td>
</tr>
<tr>
<td>OKTA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$14.35</td>
<td>$14.15</td>
<td>$14.29</td>
<td>$110.00</td>
<td>$48.5K</td>
<td>5</td>
<td align="right">65</td>
</tr>
<tr>
<td>OKTA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$15.15</td>
<td>$15.1</td>
<td>$15.15</td>
<td>$115.00</td>
<td>$46.9K</td>
<td>1.9K</td>
<td align="right">93</td>
</tr>
<tr>
<td>OKTA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$3.95</td>
<td>$3.8</td>
<td>$3.9</td>
<td>$105.00</td>
<td>$39.0K</td>
<td>214</td>
<td align="right">119</td>
</tr>
</tbody>
</table>

<h3>About Okta</h3>
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Having examined the options trading patterns of Okta, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Okta's Current Market Status</h3>
<ul>
<li>With a trading volume of 1,451,294, the price of OKTA is down by -2.69%, reaching $105.08.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 58 days from now.</li>
</ul>
<h3>What The Experts Say On Okta</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $112.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Perform rating for Okta, targeting a price of $109. 
&#x2A; An analyst from Stifel persists with their Buy rating on Okta, maintaining a target price of $120. 
&#x2A; An analyst from Goldman Sachs has decided to maintain their Buy rating on Okta, which currently sits at a price target of $123. 
&#x2A; An analyst from Citigroup persists with their Neutral rating on Okta, maintaining a target price of $110. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Equal-Weight rating for Okta, targeting a price of $100. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Okta options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

OKTA

Okta's Options Frenzy: What You Need to Know

Press Releases

Twist Bioscience Announces Fiscal 2024 Fourth Quarter and Full Year Financial Results

Small Cap

Opinion

AI's Growing Role in Transforming Healthcare Delivers Innovations in Diagnostics, Patient Care

Twist Bioscience to Present at 43rd Annual J.P. Morgan Healthcare Conference

Twist Bioscience to Report Fiscal 2025 First Quarter Financial Results on Monday, February 3, 2025

Economics

Gene Synthesis Market Size to Surpass USD 9.54 Billion by 2033 | Straits Research

Twist Bioscience Announces Fiscal 2025 First Quarter Financial Results

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience to Present at Upcoming Investor Conferences

Twist Bioscience Offers Clonal Genes for Global Academic Researchers at Express Speed for No Extra Cost

Twist Bioscience and Curio Genomics Collaborate to Accelerate and Streamline NGS Adoption in Agrigenomics

ABSI

AVAI

RDNT

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Alvotech

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Beam Therapeutics

Biohaven

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Denali Therapeutics

Amicus Therapeutics

ImmunityBio

Kymera Therapeutics

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Soleno Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

Vericel

Veracyte

Viking Therapeutics

Scotiabank

JP Morgan

Baird

Wolfe Research

TD Cowen

2025년 2월 28일 금요일 캐시 우드의 아크 인베스트가 몇 가지 주목할 만한 거래를 진행했다. 그중 가장 두드러진 것은 아처 에비에이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>), 리커션 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), 템퍼스AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), 그리고 이리디움 커뮤니케이션스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>)의 주식을 매수한 것이다.
반면 아크 인베스트는 트위스트 바이오사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>), 아디옌(OTC:<a class="ticker" href="https://www.benzinga.com/stock/ADYEY#OTC">ADYEY</a>), 애콜레이드 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>), 그리고 이그젝트 사이언스(NCM:EXAS)의 주식을 매도하기로 결정했다.
<h3>아처 에비에이션 거래</h3>
아크 인베스트는 아처 아비에이션의 주식을 세 개의 ETF를 통해 상당량 매수했다. ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)가 360,583주, ARK Autonomous Technology &amp; Robotics ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>)가 54,699주, ARK Space Exploration &amp; Innovation ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>)가 17,322주를 매수했다.
금요일 종가 8.88달러 기준 아처 에비에이션 매수 거래 총 가치는 약 380만 달러이다.
<h3>리커션 파마슈티컬스 및 템퍼스AI 거래 </h3>
아크 인베스트는 리커션 파마슈티컬스와 템퍼스AI에도 강한 관심을 보였다. <a href="https://www.benzinga.com/markets/equities/25/02/43963343/cathie-woods-buys-the-dip-in-tempus-ai-coinbase-but-sells-arks-bitcoin-etf-shares-amid-crypto-meltdown">이전에</a> 아크 인베스트는 템퍼스AI의 주식을 상당량 매수했지만, 4분기 엇갈린 실적 발표 이후 템퍼스AI 주가는 하락했다.
아크 인베스트의 ARK Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)가 리커션 파마슈티컬스 주식 268,467주와 템퍼스AI의 주식 32,467주를 매수했다.
또한 ARK Innovation ETF가 리커션 파마슈티컬스 주식 384,956주와 템퍼스AI의 주식 49,250주를 매수했다.
템퍼스AI의 경우 종가 56.18달러, 리커션 파마슈티컬스 경우 종가 7.51달러 기준, 이 거래의 총 가치는 각각 3,670만 달러, 61만 달러이다.
<h3>기타 거래</h3>
아크 인베스트의 의 ARK Innovation ETF가 이리디움 커뮤니케이션스의 주식 73,659주를 매수한 반면, 트위스트 바이오사이언스의 주식 65,290주를 매도했다.
또한 ARK Next Generation Internet ETF가 아디옌의 주식 52주를 소량 매도했다.
그리고 ARK Genomic Revolution ETF는 이그젝트 사이언스의 주식 80,270주와 애콜레이드의 주식 232주를 매도했다.
면책 조항: 이 콘텐츠는 부분적으로 AI 도구의 도움을 받아 생성되었으며, Benzinga 편집자가 검토하고 게시했습니다.
사진 출처: 아크 인베스트
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

금요일에 캐시 우드가 이끄는 아크 인베스트가 이리듐 커뮤니케이션스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>), 트위스트 바이오사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>), 페이저듀티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>), 빔 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), 로쿠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>), 그리고 아이보타(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NASDAQ">IBTA</a>)와 같은 주식들에 대해 중요한 거래를 진행했다.
IRDM 거래
아크 인베스트는 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 통해 이리듐 커뮤니케이션스의 주식 86,666주를 매수했다.
금요일에 IRDM의 종가가 31.63달러이었으므로, 이 거래의 총 가치는 약 274만 달러입니다. 이 움직임은 IRDM 주가가 약간 하락한 가운데 이루어졌으며, 금요일에 주가가 1.13% 변화했다.
TWST 거래
아크 인베스트는 또한 ARKK를 통해 트위스트 바이오사이언스의 주식 36,806주를 구매했다.
종가가 47.59달러였으므로, 이 거래의 총 가치는 약 175만 달러이다. TWST의 주가가 금요일에 1.5% 이상 급등했다.
PD 거래
아크 인베스트는 ARKK를 통해 페이저듀티의 주식 35,546주를 매수하고, 추가로 ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)를 통해 10,215주를 매수했다.
금요일에 PD의 종가가 19.3달러이었으므로, 이 거래의 총 가치는 약 882,000달러이다.
기타 주요 거래:
<ul>
<li>아크 인베스트는 아이보타(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NASDAQ">IBTA</a>)의 주식 24,250주를 ARK Fintech Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>)를 통해 매수했다.</li>
<li>아크 인베스트는 빔 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>)의 주식 1,916주를 ARK Genomic Revolution ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#NYSE">ARKG</a>)와 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 통해 매수했다.</li>
<li>아크 인베스트는 로쿠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>)의 주식 46,810주를 ARKK와 ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)를 통해 매도했다.</li>
</ul>
이 거래들은 기술 섹터의 역동적인 성과에 대한 아크 인베스트의 전략적 결정을 반영한다.
 
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/25/02/43755136/bill-gates-wanted-a-friend-to-take-charge-of-microsoft-due-to-regret-over-leaving-harvard-but-heres-why-he-panick">빌 게이츠는 하버드를 떠난 것을 후회하여 친구가 마이크로소프트의 &#8216;책임을 맡기를 원했지만, 그가 패닉에 빠져 중퇴한 이유는?</a></li>
</ul>
면책 조항: 이 콘텐츠는 AI 도구의 도움을 받아 부분적으로 생성되었으며, Benzinga 편집자에 의해 검토 및 게시되었습니다.
이미지 제공: Ark Invest


Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

캐시 우드가 이끄는 아크 인베스트가 월요일(10일)에 상당한 규모의 거래를 했다. 가장 눈에 띄는 것은 팔란티어 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) 주식의 매각이었는데, 팔란티어 주가가 인상적인 재무 실적 이후 계속 상승세를 이어가고 있었기 때문이다.
<h3>팔란티어 거래</h3>
월요일, 아크 인베스트가 팔란티어의 ARKK ETF를 통해 135,775주를 매각하는 주목할 만한 거래를 실행했다. 이 움직임은 팔란티어의 주가가 인상적인 <a href="https://in.benzinga.com/news/earnings/earnings-beats/25/02/43468342/palantir-rockets-on-strong-q4-2024-was-only-a-dress-rehearsal-for-ai-growth-says-analyst" target="_blank" rel="noopener">4분기 실적 보고서를 발표</a>하고 주가가 <a href="https://www.benzinga.com/25/02/43550434/cathie-wood-dumps-10-million-palantir-shares-at-peak-sells-robinhood-and-reddit-ark-invest-loads-up-on-qualcomm-stock" target="_blank" rel="noopener">사상 최고치를 경신한 이후에 나온 것이다</a>. 팔란티어는 매출 8억 2,752만 달러를 기록해 애널리스트들의 예상치인 7억 7,591만 달러를 넘어섰고, 주당 14센트의 조정 수익을 기록해 주당 11센트의 예상치를 상회했다.
팔란티어의 월요일 종가는 116.65달러로 5.23% 상승했다. 52주 최고가는 116.76달러였고, 월요일 시간외 거래에서는 117.56달러에 거래되었다. 월요일 종가를 기준으로 아크 인베스트의 팔란티어 매각액은 약 1,583만 달러에 달한다. 아크 인베스트는 인상적인 재무 실적에도 불구하고 팔란티어에 대한 지분을 <a href="https://www.benzinga.com/25/02/43550434/cathie-wood-dumps-10-million-palantir-shares-at-peak-sells-robinhood-and-reddit-ark-invest-loads-up-on-qualcomm-stock" target="_blank" rel="noopener">전략적으로 줄이고 있다.</a>
<h3>기타 주요 거래</h3>
<ul>
<li>유아이패스 (PATH) – ARKK 통해 459,205주, ARKW 통해 33,061주 매각</li>
<li>로쿠 (ROKU) – ARKK 통해 78,654주 매각</li>
<li>트위스트 바이오사이언스 (TWST) – ARKK 통해 268,210주 매입</li>
<li>일루미나 (ILMN) – ARKK 통해 85,621주, ARKG 통해 14,846주 매입</li>
</ul>
이미지 출처: Shutterstock
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal">Shivdeep Dhaliwal</a>이 편집했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

금요일에 캐시 우드의 아크 인베스트가 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), 로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), 팔란티어 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) 그리고 로블록스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) 등 여러 주요 기업의 주식에 대해 중요한 거래를 진행했다.
AMZN 거래
아크 인베스트는 ARK Fintech Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>), ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>), ARK Autonomous Technology &amp; Robotics ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>), ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) 그리고 ARK Space Exploration &amp; Innovation ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) 펀드를 통해 아마존닷컴 주식을 구매했다. 모든 ETF를 합쳐 총 72,457주의 주식을 매수했다.
아마의 당일 종가가 229.15달러였음을 감안할 때, 총 매입금액은 1,660만 달러이다.
로블록스 거래
아크 인베스트는 ARKF, ARKK 그리고 ARKW 펀드를 통해 로블록스 주식 48,541주를 매수했다. 로블록스 주식의 금요일 종가가 66.28달러일 때, 이 거래의 가치는 321만 달러이다.
일루미나 거래
아크 인베스트는 ARKG와 ARKK 펀드를 통해 일루미나 주식 107,459주를 매수했다. 금요일 일루미나 주식의 종가가 111.06달러일 때, 이 거래의 가치는 1,193만 달러이다.
PLTR 거래
아크 인베스트는 ARKF 펀드에서 팔란티어 주식 8,150주를 매도했다. 금요일 팔란티어 주식의 종가가 110.85달러일 때, 이 거래의 가치는 903,428달러이다. 알렉스 카프가 이끄는 이 회사는 목요일에 주가가 116달러로 사상 최고가를 기록했다.
기타 주요 거래
<ul>
<li>애콜레이드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>): ARKG 펀드를 통해 401,962주 매도.</li>
<li>트위스트 바이오사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>): ARKG와 ARKK 펀드를 통해 44,562주 매수.</li>
<li>10X 지노믹스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>): ARKG와 ARKK 펀드를 통해 185,249주 매수.</li>
<li>페이저듀티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>): ARKK와 ARKW 펀드를 통해 85,420주 매수.</li>
<li>클라우드플레어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>): ARKW 펀드를 통해 18,319주 매도.</li>
<li>유아이패스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>): ARKK와 ARKW 펀드를 통해 996,441주 매도.</li>
<li>로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>): ARKF, ARKK, ARKW 펀드를 통해 113,777주 매도.</li>
<li>로켓랩 USA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>): ARKQ와 ARKX 펀드를 통해 70,252주 매도.</li>
</ul>
다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%A0%84%EC%84%A4%EC%A0%81%EC%9D%B8-%EA%B3%B5%EB%A7%A4%EB%8F%84-%ED%88%AC%EC%9E%90%EC%9E%90-%EC%A7%90-%EC%B0%A8%EB%85%B8%EC%8A%A4-%EC%97%AD%EC%82%AC%EC%A0%81%EC%9D%B8-%EA%B7%B9%EB%8B%A8%EC%97%90/" target="_blank" rel="noopener">전설적인 공매도 투자자 짐 차노스가 시장 투기가 역사적 극단치에 이르렀다고 경고했습니다: ‘월스트리트도 화폐 인쇄기가 있습니다&#8217;</a></li>
</ul>
사진 출처: Ark Invest
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Short Sellers

AMZN

HOOD

RBLX

RKLB

아크 인베스트는 팔란티어 지분을 줄이고 아마존, 로블록스 및 일루미나에 대한 큰 베팅

아크 인베스트먼트 매니지먼트 설립자이자 CEO인 캐시 우드는 최근 소파이(SoFi)의 투자 전략 책임자 리즈 토마스(Liz Thomas)와 함께 출연한 팟캐스트에서 기술 혁신의 초석으로 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)를 강조하고, 인공지능(AI) 투자의 미래를 옹호했다.
무슨 일 있었나: ARK 이노베이션 ETF를 이끄는 것으로 널리 알려진 캐시 우드는 테슬라를 "지구상에서 가장 큰 AI 프로젝트"라고 표현하며 여러 분야에 걸쳐 AI의 혁신적 잠재력을 강조했다.
특히 AI와 시퀀싱 기술의 융합이 혈액 검사를 통한 암 진단, 특히 크리스퍼 유전자 편집 기능과 결합될 경우 암 진단에 혁신을 가져올 수 있는 의료 분야의 발전에 주목했다.
우드는 주요 기술 기업들의 막대한 GPU 및 클라우드 인프라 투자에 대한 우려를 언급하며 자본 지출 증가에 대한 투자자들의 회의적인 시각도 인정했다.
그는 아직 명확한 수익이 입증되지 않은 투자의 예로 18개월 만에 300억 달러에서 600억 달러로 지출이 급증한 마이크로소프트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)를 들었다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%BA%90%EC%8B%9C-%EC%9A%B0%EB%93%9C-%EB%B0%94%EC%9D%B4%EC%98%A4-%EB%B6%84%EC%95%BC%EC%97%90%EC%84%9C-4%EC%B2%9C%EC%96%B5-%EB%8B%AC%EB%9F%AC-%EA%B8%B0%ED%9A%8C-%EC%A0%84%EB%A7%9D/">캐시 우드, 바이오 분야에서 4천억 달러 기회 전망</a>
왜 중요한가: 캐시 우드의 이번 발언은 주력 펀드를 통해 테슬라 보유 자산을 1,800만 달러 줄이는 등 최근 포트폴리오 조정 과정 속에 나왔다. 이러한 매각에도 불구하고 우드는 "1조 달러 이상의 수익 기회"를 예상하며 테슬라의 <a href="https://www.benzinga.com/24/11/42205945/ark-invests-bold-move-tesla-shares-sold-amid-market-shifts" target="_blank" rel="noopener">자율주행 잠재력</a>에 대해 낙관적인 장기 전망을 유지하고 있다.
우드의 투자 논리는 테슬라를 넘어 광범위한 생물학 분야로 확장되어 AI, 유전자 염기서열 분석, <a href="https://www.benzinga.com/general/biotech/24/11/42206182/cathie-wood-sees-400b-opportunity-in-biologics-how-have-her-bets-fared" target="_blank" rel="noopener">유전자 편집 기술</a>의 융합으로 4,000억 달러의 시장 기회가 창출될 것으로 예상하고 있다.
11억 7,900만 달러의 자산을 운용하는 ARK Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)는 이러한 신념을 반영하여 트위스트 바이오사이언스 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>), CRISPR 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) 같은 회사에 상당한 투자를 단행했다.
우드는 시장 밸류에이션 상승에 대한 우려에 대해 현재 20대 초반의 시장 멀티플은 오류의 여지가 거의 없다고 지적했다. 그러나 특히 AI와 의료 혁신의 교차점에서 <a href="https://www.benzinga.com/general/biotech/24/11/42206182/cathie-wood-sees-400b-opportunity-in-biologics-how-have-her-bets-fared" target="_blank" rel="noopener">질병 치료 및 진단</a>의 혁신적인 발전 가능성을 보는 비즈니스 모델의 출현에 대해 여전히 확신을 가지고 있다.
이미지 출처: 아크 인베스트
면책 조항: 이 기사는 부분적으로 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>의 도움으로 작성되었으며 Benzinga 편집자가 검토 후 게시했습니다.
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Global

CRSP

MSFT

TSLA

캐시 우드 "테슬라는 지구상에서 가장 큰 AI 프로젝트", 기술 투자에 대해 우려하지 않아

아크 인베스트의 CEO인 캐시 우드는 인공지능, 유전자 염기서열(시퀀싱) 분석, 유전자 편집 기술의 교차점에서 전례 없는 잠재력을 발견하고 바이오 분야에 투자를 강화하고 있다.
무슨 일 있었나: 캐시 우드의 열정은 의료와 신약 개발에 혁명을 일으킬 수 있는 혁신적인 기술 융합에 집중되어 있다.
그는 이 분야에 대해 솔직하게 이야기하면서 특히 크리스퍼 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>), 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), 빔 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) 같은 회사에서 유전자 치료의 괄목할 만한 발전이 이루어지고 있다고 강조했다.
가장 눈에 띄는 사례는 최근 크리스퍼 테라퓨틱스가 겸상 적혈구 질환 치료 분야에서 거둔 획기적인 성과다. 우드는 이전에는 연간 12~20회 수혈을 받아야 했던 환자들이 이제 그런 수혈을 받지 않아도 될 수 있게 되었다고 언급했다.
이러한 전략은 치료의 혁신을 넘어 신약 개발 자체로 확장횐다. 우드는 리커션 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>)와 같은 회사가 인공지능을 활용하여 임상시험 실패율을 획기적으로 줄이고 신약 개발 일정을 앞당기고 있다고 강조했다.
그러나 이러한 혁신적인 기업들의 시장 성과는 좀 더 복잡한 이야기를 담고 있다. 올해 들어 이들 주식은 상당한 변동성을 보였다. <a href="//www.benzinga.com/pro/"" target="_blank" rel="noopener">벤징가 프로 데이터</a>에 따르면 연초 대비 크리스퍼 테라퓨틱스는 25.36% 하락, 인텔리아 테라퓨틱스는 52.21% 하락, 빔 테라퓨틱스는 3.04% 하락, 리커션 제약은 9.80% 하락했다.
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Which market sector excites <a href="https://twitter.com/CathieDWood?ref_src=twsrc%5Etfw">@CathieDWood</a> the most and why? In <a href="https://twitter.com/hashtag/askARK?src=hash&amp;ref_src=twsrc%5Etfw">#askARK</a>, she shares her growing enthusiasm for the biologics space.
Have more questions for Cathie? Share them in the comments. <a href="https://t.co/WjilZChce6">pic.twitter.com/WjilZChce6</a>
&mdash; ARK Invest (@ARKInvest) <a href="https://twitter.com/ARKInvest/status/1861431767506268404?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%BA%90%EC%8B%9C-%EC%9A%B0%EB%93%9C%EC%9D%98-%EC%95%84%ED%81%AC-%EC%9D%B8%EB%B2%A0%EC%8A%A4%ED%8A%B8-%ED%85%8C%EC%8A%AC%EB%9D%BC-%EC%A3%BC%EC%8B%9D-1800%EB%A7%8C-%EB%8B%AC%EB%9F%AC-%EC%83%81/" target="_blank" rel="noopener">캐시 우드의 아크 인베스트, 테슬라 주식 1,800만 달러 상당 매각</a>
왜 중요한가: 바이오 분야에 대한 아크 인베스트의 노력은 11억 7,900만 달러의 순자산을 관리하는 Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)를 통해 분명하게 드러난다. 이 펀드의 성과는 2020년 최고 180.50%에서 2022년 최저 -53.94%에 이르는 연간 수익률로 해당 섹터의 변동성을 반영하고 있다.
이 ETF의 현재 상위 보유 종목은 혁신적인 바이오 기술에 대한 캐시 우드의 전략적 초점을 강조한다. 트위스트 바이오사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>)가 8.90%의 비중으로 포트폴리오를 이끌고 있으며, 크리스퍼 테라퓨틱스가 7.88%, 리커션 파마슈티컬스가 6.17%로 그 뒤를 잇고 있다. 그 밖의 주요 투자 기업으로는 케어DX(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), 베라사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), 어댑티브 바이오테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) 등이 있으며, 이들은 게놈 및 생물학적 혁신에 대한 다양한 접근 방식을 대표한다.
캐시 우드는 AI, 시퀀싱 기술, 유전자 편집의 전례 없는 융합 덕분에 향후 5년 동안 바이오 분야에서 4,000억 달러의 시장 기회가 있을 것으로 전망한다.
이미지 출처: Ark Invest
면책 조항: 이 콘텐츠는 부분적으로 AI 도구의 도움을 받아 생성되었으며, Benzinga 편집자가 검토 후 게시했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

ADPT

CDNA

NTLA

VCYT

캐시 우드, 바이오 분야에서 4천억 달러 기회 전망

캐시 우드가 이끄는 아크 펀드(Ark Funds)는 미래 성장 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41593922/cathie-woods-ark-invest-sees-tesla-unlocking-11-trillion-revenue-potential-with-rob" target="_blank" rel="noopener" data-google-interstitial="false">혁신 분야</a>에 중점을 두고 적극적으로 관리되는 ETF들 덕분에 가장 잘 알려진 펀드 매니저 중 하나이다.
이 펀드의 ETF 두 개가 목요일에 10주년을 맞이했다. 이들 펀드의 출시와 지난 10년 동안의 성과를 살펴보겠다.
아크 이노베이션: 우드와 <a href="https://www.benzinga.com/topic/ark-funds">아크 펀드</a>는 Ark Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 2014년 10월 31일에 출시했다. 이 펀드는 이 회사의 가장 유명하고 가장 큰 펀드로 성장했으며, 현재 57억 8천만 달러의 운용 자산을 보유하고 있다.
&#8220;ARRK는 자본의 장기적 성장을 추구하는 액티브하게 관리되는 ETF로, 일반적으로 국내 및 해외 주식에 주로 투자하여 펀드의 투자 테마인 파괴적 혁신(disruptive innovation)와 관련된 회사들에 투자한다&#8221;고 이 회사의 <a href="https://www.ark-funds.com/funds/arkk">웹사이트</a>에서 설명한다.
파괴적 혁신 테마에는 자율 이동성, 정밀 치료, 차세대 클라우드, 신경망, 지능형 기기, 디지털 지갑, 디지털 자산, 스마트 계약 및 멀티오믹 기술이 포함된다.
&#8220;ARK는 &#8216;파괴적 혁신&#8217;을 세상이 돌아가는 방식에 잠재적으로 도전할 수 있는 기술적으로 구현된 새로운 제품이나 서비스의 도입으로 정의한다.&#8221;
현재 ARKK ETF의 상위 10개 보유 종목과 그 순자산 비율은 다음과 같다:
<ol>
<li>테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>): 14.1%</li>
<li>로쿠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>): 10.8%</li>
<li>코인베이스 글로벌 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>): 8.1%</li>
<li>로블록스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>): 6.2%</li>
<li>팔란티어 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>): 5.1%</li>
<li>로빈후드 마켓 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>): 5.0%</li>
<li>블록 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>): 4.9%</li>
<li>크리스퍼 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>): 4.5%</li>
<li>쇼피파이 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>): 3.9%</li>
<li>유아이패스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>): 2.9%</li>
</ol>
이 펀드 설립 이래로 이 ETF의 수익률은 161.4% 상승했다. 이 수익률은 S&amp;P 500을 추적하는 SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)의 현재 10년 수익률에는 미치지 못한다.
아래의 표는 ARKK의 수익률이 SPY와 어떻게 비교되는지를 보여준다. SPY는 <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/10/41407647/spy-reaches-600-billion-in-assets-oldest-us-ETF-hits-milestone-as-all-time-highs-conti">가장 오래되고 가장 큰</a> 미국 ETF이다:
<figure class="wp-block-table">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>평균 연간 수익률</td>
<td>ARKK</td>
<td>SPY</td>
</tr>
<tr>
<td>1년</td>
<td>+19.9%</td>
<td>+36.2%</td>
</tr>
<tr>
<td>3년</td>
<td>-24.3%</td>
<td>+11.8%</td>
</tr>
<tr>
<td>5년</td>
<td>+2.6%</td>
<td>+15.8%</td>
</tr>
<tr>
<td>ARKK 설립 이래 2014년 10월 31일 기준</td>
<td>+10.2%</td>
<td>+13.2%</td>
</tr>
</tbody>
</table>
</figure>
아래의 차트는 <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1">Benzinga Pro</a>에서 제공한 ARKK의 10년 수익률을 보여준다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-624517" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224.png" sizes="(max-width: 1003px) 100vw, 1003px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224.png 1003w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224-768x393.png 768w" alt="" width="1003" height="513" /></a></figure>
비교를 위해 SPY의 10년 차트도 보여드리겠다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-624522" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226.png" sizes="(max-width: 995px) 100vw, 995px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226-768x392.png 768w" alt="" width="995" height="508" /></a></figure>
다음 읽어보기: <a href="https://www.benzinga.com/markets/penny-stocks/23/08/34102486/exclusive-cathie-wood-tells-benzinga-why-tesla-should-trade-as-a-tech-stock">독점: 캐시 우드가 테슬라가 기술 주식으로 거래되어야 하는 이유를 Benzinga에 말했다.</a>
아크 지노믹스: Ark Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)는 2014년 10월 31일에 아크 펀드에 의해 출시되었다. 현재 이 ETF 펀드는 13억 3천만 달러의 자산을 운용하고 있다.
&#8220;ARKG는 자본의 장기적 성장을 추구하는 액티브하게 관리되는 ETF로, 일반적으로 헬스 케어, 정보 기술, 소재, 에너지 및 소비재 등 여러 섹터의 국내외 주식에 주로 투자하며, 펀드의 투자 테마인 유전체 혁명(genomics revolution)과 관련된 회사들에 투자한다&#8221;고 이 회사의 <a href="https://www.ark-funds.com/funds/arkg">웹사이트</a>에서 설명한다.
이 유전체 혁명 ETF의 테마에는 정밀 치료, 멀티오믹 기술, 프로그래머블 생물학, 신경망, 차세대 클라우드 및 적응형 로보틱스가 포함된다.
현재 ARKG ETF의 상위 10개 보유 종목과 그 순자산 비율은 다음과 같다:
<ol>
<li>트위스트 바이오사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>): 8.7%</li>
<li>리커젼 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>): 7.0%</li>
<li>크리스퍼 테라퓨틱스: 7.0%</li>
<li>케어Dx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>): 5.1%</li>
<li>어댑티브 바이오테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>): 4.7%</li>
<li>베라사이트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYCT#NASDAQ">VYCT</a>): 4.6%</li>
<li>아이오니스 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>): 4.3%</li>
<li>누릭스 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>): 4.1%</li>
<li>나테라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>): 3.8%</li>
<li>10x 지노믹스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>): 3.8%</li>
</ol>
이 펀드 설립 이래로 이 ETF의 수익률은 38.9% 상승했다. 이 수익률은 현재 SPDR S&amp;P 500 ETF Trust의 10년 수익률에는 미치지 못한다.
ARKG의 수익률이 SPY와 어떻게 비교되는지를 살펴보겠다.
<figure class="wp-block-table">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>평균 연간 수익률</td>
<td>ARKG</td>
<td>SPY</td>
</tr>
<tr>
<td>1년</td>
<td>-7.9%</td>
<td>+36.2%</td>
</tr>
<tr>
<td>3년</td>
<td>-29.9%</td>
<td>+11.8%</td>
</tr>
<tr>
<td>5년</td>
<td>-1.9%</td>
<td>+15.8%</td>
</tr>
<tr>
<td>ARKG 설립 이래 2014년 10월 31일 기준</td>
<td>+3.3%</td>
<td>+13.2%</td>
</tr>
</tbody>
</table>
</figure>
다음은 ARKG의 10년 차트다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-624525" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225.png" sizes="(max-width: 993px) 100vw, 993px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225-768x394.png 768w" alt="" width="993" height="510" /></a></figure>
중요성 (Why It&#8217;s Important): 위의 차트들은 ARKK와 ARKG가 모두 투자자들에게 몇 년 동안 강력한 성장과 수익률을 경험했지만, 최근 몇 년 동안은 더 넓은 S&amp;P 500 시장 지수를 하회한 것을 보여준다.
한때 이 ETF들은 가장 화제가 된 펀드들 중 하나였으며, 이 회사의 일일 거래 활동은 종종 주식을 상승시켰다. 이는 우드의 뛰어난 성과 덕분이다.
S&amp;P 500 ETF는 분기마다 리밸런싱을 하지만, 이 액티브하게 관리되는 펀드는 거의 매일 거래를 완료한다. 종종 주가가 상승하는 주식의 평균 매입가가 시간이 지남에 따라 상승하여 수익률에 부정적인 영향을 미칠 수 있다.
아크 펀드는 일반적으로 향후 5년에서 10년 동안 강력한 성장을 할 것으로 믿는 회사들에 투자한다. 이는 펀드의 수익률이 때때로 몇 년이 걸려야 나타날 수 있음을 의미한다.
우드는 엔비디아의 주식을 2014년에 약 5달러에 매수한 것과 같이 많은 테마에 대해 일찍 투자한 바 있다. 이는 가장 최근의 주식 분할 이전의 일이었다. 이 펀드는 나중에 2022년 말과 2023년 초에 이 포지션에서 완전히 매도하여 지난 2년 가까이 <a style="font-size: revert;" href="https://www.benzinga.com/general/education/24/02/37294405/heres-how-much-cathie-wood-ark-invest-flagship-fund-missed-by-selling-nvidia-early">엄청난 수익을 놓쳤</a>다.
이 펀드 매니저는 또한 테슬라 성장 스토리에 일찍 투자했다. 2018년 2월에 이 전기차 회사에 대해 $4,000 목표 주가를 <a href="https://www.benzinga.com/news/22/03/26046331/if-you-invested-1-000-in-tesla-when-cathie-wood-made-her-4-000-prediction-heres-how-much-youd-have-n-1" target="_blank" rel="noopener">예측</a>했다. 당시에는 가격 예측으로 비웃음거리가 되었지만, 주가는 2021년 1월에 분할 기준으로 목표 주가에 도달했다.
테슬라에 대한 예측이 맞아들어간 것은 우드의 펀드 매니저로서의 위상을 높이는 데 도움이 되었고, 아크 펀드 ETF들에 대한 관심이 증가하는 계기가 되었다.
최근 몇 년 동안 아크 펀드 ETF들에 대한 관심이 식었지만, 많은 투자자들은 여전히 그들의 영향을 기억하고 일일 거래 활동을 계속 추적하며, 우드가 향후 5년에서 10년 동안 보유할 주식을 주의 깊게 지켜보고 있다.

다음 읽어보기:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/23/08/34028505/exclusive-why-does-cathie-wood-think-bitcoin-is-going-to-1-million-what-does-she-know-that">독점: 캐시 우드는 왜 비트코인이 100만 달러에 이를 것이라고 생각하는가? 그녀는 무엇을 알고 있기에?</a></li>
</ul>
이미지 제공: Ark Invest 및 Shutterstock.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Twist Bioscience

뉴스

에 대한 최신 뉴스 Twist Bioscience (NASDAQ:TWST) 주식

토요일, 3월 01, 2025

토요일, 2월 15, 2025

화요일, 2월 11, 2025

일요일, 2월 09, 2025

금요일, 11월 29, 2024

수요일, 11월 27, 2024

금요일, 11월 01, 2024

월요일, 9월 16, 2024

목요일, 5월 09, 2024

수요일, 5월 08, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌